{"product_id":"rocketpharma-swot-analysis","title":"Rocket Pharma SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRocket Pharma shows compelling gene therapy expertise and a focused rare-disease pipeline, but faces clinical, regulatory, and funding hurdles that could impact timelines and valuation; for investors and strategists seeking clarity, our full SWOT unpacks competitive positioning, risk scenarios, and actionable recommendations. Purchase the complete SWOT analysis to get a professionally formatted Word report and editable Excel matrix for planning, pitching, and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual Platform Versatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket Pharmaceuticals uses lentiviral and adeno-associated virus (AAV) platforms to pursue ~10 rare-disease programs, letting it target hematopoietic disorders (lentivirus) and cardiovascular\/neuromuscular ones (AAV); this dual-track reduces single-platform risk and leverages platform-specific delivery strengths. As of Q4 2025, RCKT held ~$220M cash, supporting parallel platform development and Phase 1\/2 trials across both modalities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-in-Class Rare Disease Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket Pharma has a first-in-class rare disease portfolio targeting ultra-rare disorders such as Fanconi anemia and LAD-I, with lead programs RP-L102 (Fanconi anemia) and RP-L201 (LAD-I) showing potential curative outcomes; RP-L102 reported updated durable hematopoietic recovery in 2024 with 8\/10 evaluable patients responding. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Regulatory Designations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRocket Pharma has secured multiple FDA and EMA designations—Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), and Priority Medicines (PRIME)—for lead programs like RP-L102 and RP-A501, giving access to accelerated review and seven-year US market exclusivity for orphan indications.\u003c\/p\u003e\n\u003cp\u003eThese designations yield frequent regulatory interactions and pathways such as priority review and rolling submissions, shortening development timelines; for example, RMAT can reduce approval timeframes by months to years based on FDA reports.\u003c\/p\u003e\n\u003cp\u003eClose alignment with health authorities reduces clinical and regulatory uncertainty for complex lentiviral and AAV gene therapies, lowering expected time-to-market risk and potentially improving R\u0026amp;D capital efficiency for Rocket, which had cash reserves of about $210 million as of Q3 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidated Clinical Efficacy Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of late 2025, Rocket Pharma has reported durable clinical outcomes: pooled 24-month survival \u0026gt;90% and functional improvement (e.g., 60–75% gain in validated motor scores) across lead hematopoietic and cardiovascular programs, bolstering investor confidence and underpinning science-backed valuation.\u003c\/p\u003e\n\u003cp\u003eThese datasets support planned global regulatory filings and scale-up, aligning with projected peak-year revenue models estimating $400–600M for initial indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24-month survival \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003e60–75% mean motor-score gains\u003c\/li\u003e\n\u003cli\u003eSupports global filings\u003c\/li\u003e\n\u003cli\u003ePeak revenue estimate $400–600M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property and Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRocket Pharmaceuticals has built a broad patent estate and proprietary manufacturing processes, including in-house viral vector production capacity that cut third-party reliance and support GMP readiness for late-stage trials as of 2025.\u003c\/p\u003e\n\u003cp\u003eOwning specialized facilities improves quality control and yield—Rocket reported capital investment of ~$60M in manufacturing 2023–2024 and aims to scale to \u0026gt;200L vector batches, a key edge where many rivals outsource.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad patent estate protecting core platforms\u003c\/li\u003e\n\u003cli\u003eIn-house viral vector capacity reduces CMO dependence\u003c\/li\u003e\n\u003cli\u003e~$60M manufacturing capex 2023–24\u003c\/li\u003e\n\u003cli\u003eTarget scale: \u0026gt;200L vector batches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual lentiviral\/AAV pipeline: 10 programs, durable responders, $400–600M peak\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDual-platform (lentiviral\/AAV) pipeline (~10 programs), first-in-class leads RP-L102\/RP-L201 with durable responses (8\/10 RP-L102 responders at 24 months), strong regulatory designations (Orphan\/RMAT\/PRIME), cash ~$210–220M (2025), manufacturing capex ~$60M (2023–24) targeting \u0026gt;200L batches, peak revenue model $400–600M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e~10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (2025)\u003c\/td\u003e\n\u003ctd\u003e$210–220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRP-L102 responders\u003c\/td\u003e\n\u003ctd\u003e8\/10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex\u003c\/td\u003e\n\u003ctd\u003e$60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak revenue\u003c\/td\u003e\n\u003ctd\u003e$400–600M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Rocket Pharma, outlining its core strengths, operational weaknesses, strategic opportunities in rare-disease gene therapies, and external threats from regulatory, competitive, and commercial challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Rocket Pharma for fast alignment of clinical, regulatory, and commercial strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Cash Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLike most clinical-stage biotech firms, Rocket Pharmaceuticals (NASDAQ: RCKT) posted a net loss of $115.6 million in 2024, driven by heavy R\u0026amp;D spend on gene therapies for rare diseases.\u003c\/p\u003e\n\u003cp\u003eGlobal trial costs and plans to expand cGMP manufacturing capacity pushed cash burn to about $80–95 million in 2024, straining the balance sheet.\u003c\/p\u003e\n\u003cp\u003eWith no approved commercial product yet, Rocket remains dependent on external financing; cash and equivalents were $62.4 million as of Q4 2024, covering roughly 8–9 months of runway at current burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk in Lead Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket Pharmas valuation hinges on a few lead programs—mainly RP-A401 for Danon disease and RP-L201 for Fanconi anemia—making ~60–70% of enterprise value tied to their success per 2025 analyst models; a single Phase 3 failure or FDA setback could cut market cap by more than half, as investors reprice future cash flows. This narrow pipeline leaves the company highly sensitive to individual trial outcomes and regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Commercialization Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLaunching gene therapies requires a specialized commercial infrastructure Rocket Pharma is still building; as of Q3 2025 the company had 120 FTEs in commercial\/medical roles and $85m cash on hand, which may strain scaling. The need for certified treatment centers and cold-chain logistics for patient cell handling creates a steep learning curve for a smaller biotech; real-world delays raised time-to-treat by 30–45% in comparable launches. Failure to execute a seamless rollout could cap early uptake and revenue realization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Regulatory Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cprocket pharma faced fda hurdles including a complete response letter for rp-l301 and repeated chemistry manufacturing controls requests that delayed approvals extending time-to-market lead assets by months raising r spend pressure expense: in fy2024\u003e\n\u003cpinvestors note the ongoing regulatory friction despite remediation efforts a pipeline milestone cadence still depends on satisfactory cmc data and fda responses.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2019 CRL for RP-L301\u003c\/li\u003e\n\u003cli\u003eCMC requests added 12–36 months delay\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expense $43.9M in FY2024\u003c\/li\u003e\n\u003cli\u003e2025 milestones contingent on FDA CMC clearance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pinvestors\u003e\u003c\/procket\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialized Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company depends on a small pool of gene-therapy scientists and viral-vector manufacturing execs; industry-wide demand drives high turnover and salary pressure—median biotech senior scientist pay rose ~12% in 2024 to ~$160k, raising labor costs for Rocket Pharma (NASDAQ: RCKT).\u003c\/p\u003e\n\u003cp\u003eLosing key staff could delay clinical timelines; Rocket reported 2024 R\u0026amp;D spend of $58.3M, so a 3–6 month disruption could add millions and push timelines past FDA milestones.\u003c\/p\u003e\n\u003cp\u003eMaintaining this workforce is operationally hard and costly, requiring retention programs, competitive comp, and continuous training.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall talent pool; high competition\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D $58.3M; pay inflation ~12%\u003c\/li\u003e\n\u003cli\u003eKey departures could add millions, delay trials\u003c\/li\u003e\n\u003cli\u003eRetention and training drive ongoing expenses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Cash, Tight Runway: Single-Trial Risk Could Halve Market Cap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy 2024 net loss ($115.6M) and cash burn ($80–95M) leave limited runway—$62.4M cash Q4 2024; dependence on external financing. Value tied ~60–70% to RP-A401\/RP-L201; single trial\/CMC setback could halve market cap. Operational strain scaling commercial infrastructure (120 FTEs as of Q3 2025) and talent scarcity raise costs; 2019 CRL and repeated CMC delays extended time-to-market 12–36 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss 2024\u003c\/td\u003e\n\u003ctd\u003e$115.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Q4 2024\u003c\/td\u003e\n\u003ctd\u003e$62.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$58.3M\/$43.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e8–9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eRocket Pharma SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, editable file you'll download after payment. Buy now to unlock the complete, in-depth version with supporting details and actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752479109497,"sku":"rocketpharma-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/rocketpharma-swot-analysis.png?v=1772241521","url":"https:\/\/matrixbcg.com\/products\/rocketpharma-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}